TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Mabpharm Limited ( (HK:2181) ) has provided an update.
Mabpharm Limited reported its financial results for the year ended December 31, 2024, showing a significant increase in revenue by 196.3% to RMB 258,228,000 compared to the previous year. Despite the revenue growth, the company recorded a loss before tax of RMB 127,947,000, which is an improvement from the previous year’s loss. The results reflect increased selling and distribution expenses and a reduction in research and development expenses, impacting the company’s financial performance and market positioning.
More about Mabpharm Limited
Mabpharm Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs. The company is listed on the Hong Kong Stock Exchange under the stock code 2181.
YTD Price Performance: 96.43%
Average Trading Volume: 110,650
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.27B
Learn more about 2181 stock on TipRanks’ Stock Analysis page.